AGL (AGL) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving AGL (AGL) right now is Margin-over-growth reset: agilon has shifted from chasing membership to prioritizing profitable contracts, exiting weaker payer relationships and markets. Revenue (TTM) is ~$5.8B. If that keeps playing out, the setup is favourable; the risk to it is agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. No one can predict where AGL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive AGL (AGL) higher?
1. Margin-over-growth reset
agilon has shifted from chasing membership to prioritizing profitable contracts, exiting weaker payer relationships and markets. This shrank Medicare Advantage membership by double digits but drove medical margin and adjusted EBITDA sharply higher in early 2026. The thesis is that a smaller, cleaner book can compound into durable earnings.
2. Improving risk-adjustment and contracting
Higher estimated risk scores, CMS benchmark benefits, and newly signed full-risk payer contracts supported a raised 2026 outlook. Getting paid appropriately for the acuity of its senior patients is central to the model, and better data and contracting terms directly lift medical margin per member.
3. Multi-year value-based care tailwind
The broader shift of Medicare from fee-for-service toward value-based, capitated care is a structural tailwind for physician-enablement platforms. agilon's long-term, market-by-market partnerships with independent primary-care groups position it to add members as more physicians take on risk.
4. Path to sustained profitability
Q1 2026 delivered positive net income and a large jump in adjusted EBITDA off a low base, with guidance for full-year adjusted EBITDA turning positive. The outlook hinges on holding these gains across all four quarters rather than in a single seasonally favorable period.
What could weigh on AGL?
agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. It is exposed to Medicare Advantage rate decisions, risk-adjustment methodology changes, and V28 model phase-in that pressure per-member revenue across the sector. The turnaround is early and depends on membership stabilizing after deliberate cuts, so profitability is not yet proven across a full year. As a small-cap with a modest share count, the stock can be volatile, and any single large market or payer contract going wrong is material. Historically it has been unprofitable on a GAAP full-year basis.
Where AGL trades today
A forecast starts from where the stock actually is. These are AGL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for AGL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a AGL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the AGL guide and whether AGL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the AGL outlook
The bottom line: what is driving AGL (AGL) is Margin-over-growth reset, with revenue (ttm) at ~$5.8B. If that keeps playing out the setup is favourable; the risk is agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. No one can predict the price, so treat any AGL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around AGL with Walnut
Use AGL as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for AGL (AGL)?
+
No one can reliably predict where AGL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push AGL higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive AGL higher?
+
The main growth drivers are Margin-over-growth reset; Improving risk-adjustment and contracting; Multi-year value-based care tailwind. Whether they play out is the real question, not a guaranteed path.
What are the risks to AGL?
+
agilon carries meaningful medical-cost-trend risk: because it is paid a fixed amount per member, an unexpected rise in senior utilization or unit costs can swing it back to losses, which is what drove heavy prior-year losses. It is exposed to Medicare Advantage rate decisions, risk-adjustment methodology changes, and V28 model phase-in that pressure per-member revenue across the sector. The turnaround is early and depends on membership stabilizing after deliberate cuts, so profitability is not yet proven across a full year. As a small-cap with a modest share count, the stock can be volatile, and any single large market or payer contract going wrong is material. Historically it has been unprofitable on a GAAP full-year basis.
Will AGL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. AGL's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is AGL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the AGL "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.